Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decay accelerating factor (CD55): a target for cancer vaccines?

I Spendlove1, L Li, J Carmichael

  • 1Cancer Research Campaign Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, United Kingdom. Ian.Spendlove@Nottingham.ac.uk

Cancer Research
|May 27, 1999
PubMed
Summary

The tumor antigen 791Tgp72 is identified as CD55, a complement regulatory protein. This finding reveals CD55

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Publisher's Note: "Ion optical design of the magnetic proton recoil neutron spectrometer for the SPARC tokamak" [Rev. Sci. Instrum. 95, 103502 (2024)].

The Review of scientific instruments·2024
Same author

Overview of the early campaign diagnostics for the SPARC tokamak (invited).

The Review of scientific instruments·2024
Same author

Overview of the neutron diagnostic systems for the SPARC tokamak.

The Review of scientific instruments·2024
Same author

Ion optical design of the magnetic proton recoil neutron spectrometer for the SPARC tokamak.

The Review of scientific instruments·2024
Same author

Design solutions for the hodoscope of the magnetic proton recoil neutron spectrometer of the SPARC tokamak.

The Review of scientific instruments·2024
Same author

Achievement of Target Gain Larger than Unity in an Inertial Fusion Experiment.

Physical review letters·2024

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • The 791Tgp72 antigen is a known target for tumor imaging and T-cell immunotherapy.
  • Characterization of this antigen is crucial for understanding its role in cancer and immune responses.

Purpose of the Study:

  • To identify and characterize the 791Tgp72 tumor antigen.
  • To elucidate the function of 791Tgp72 in immune signaling and its potential as a therapeutic target.

Main Methods:

  • Monoclonal antibody characterization (791T/36) and protein sequencing.
  • Antibody binding assays with purified antigen and transfected cells.
  • cDNA sequence analysis of tumor-derived antigen.

Main Results:

Related Experiment Videos

  • The 791Tgp72 antigen was identified as a 72/66 kDa doublet.
  • NH2-terminal sequencing and antibody binding confirmed identity with the complement regulatory protein CD55.
  • cDNA analysis showed 100% homology with CD55, and transfected cells bound the antibody.

    • Conclusions:

    • The tumor antigen 791Tgp72 is unequivocally identified as CD55.
    • CD55's role in signaling between innate and adaptive immunity suggests its significance in immune responses.
    • CD55 presents a dual potential as a therapeutic target: its absence sensitizes tumors to complement, while its overexpression allows T-cell targeting.